Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kaletra Switch for Poor Immune Responders in HIV
NCT00145795Phase 4Completed
- Sponsor
- University of Chicago
- Start
- Apr 2004
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lopinavir + ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Chicago. Primary endpoint: Immune Reconstitution at 6 months. Started Apr 2004; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00145795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00145795.